The 1.25 Billion Milestone: Corona Remedies’ Bhayla Expansion

Corona Remedies has announced an expansion of its manufacturing facility in Bhayla, increasing production capacity by 400 million units for tablets and capsules.

The expansion, which commenced on December 22, 2025, is being funded through internal accruals and is intended to meet rising market demand while strengthening the company’s in-house manufacturing capabilities. Following the expansion, the Bhayla facility’s total installed capacity will rise to 1.25 billion units.

As of March 2025, the facility had an installed capacity of 852.80 million units and was operating at a utilisation rate of 93.58 percent. Commenting on the development, a company spokesperson said the expansion aligns with Corona Remedies’ strategy to address growing demand in the pharmaceutical market and to reinforce its production capacity to support future growth.

News by Rahul Yelligetti.